MARKET IS CLOSED
Loading latest tickers...
Market Indices
S&P 500
$7,722.72
+0.73%
NASDAQ 100
$30,807.93
+1.00%
DOW JONES
$51,177.00
+0.49%
NASDAQ Composite
$27,190.86
+1.19%
RUSSELL 2000
$2,815.20
+0.90%
CBOE VIX
$15.31
-6.59%
Sector Heatmap
Technology+1.01%
Financials+0.06%
Healthcare-0.01%
Consumer Cycl+1.13%
Consumer Staples+0.25%
Energy+0.40%
Industrials+0.78%
Materials+0.66%
Real Estate+0.32%
Utilities+0.38%
Comm Services+0.35%
AVTX — Avalo Therapeutics, Inc. Common Stock
NasdaqAvalo Therapeutics, Inc. Common Stock
$14.99
+0.04(+0.27%)
- O
- 15.05
- H
- 15.16
- L
- 14.31
- V
- 948.1K
⏱️ End-of-day dataAs of Oct 2, 2026
Chart
About AVTX
Avalo Therapeutics Inc is a clinical stage biotechnology company fully dedicated to developing IL-1B-based treatments for immune-mediated inflammatory diseases. The company's asset is Abdakibart (AVTX-009) an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalos pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein), AVTX-006 and AVTX-913.
IndustryPHARMACEUTICAL PREPARATIONS
SectorNot available
IPO DateNov 13, 2015
Employees33
Stock ExchangeNasdaq
Ticker SymbolAVTX
Websitehttps://www.avalotx.com
Key Financial Statistics
| Market Cap | $829.66M |
| P/E Ratio | N/A |
| Dividend Yield | None |
| EPS | N/A |
| Beta | N/A |
| 52-Week Range | $12.51 - $24.27 |
| 52-Week Avg Volume | 954.9K |
| VWAP | $14.82 |
| Transactions | 13,895 |
| Total Recorded Bars | 2,758 days |